Every GLP-1 Savings Program in 2026: How to Pay Less

1. Manufacturer Savings Cards

Both Novo Nordisk and Eli Lilly offer savings programs for commercially insured patients:

Wegovy Savings Card: Eligible commercially insured patients may pay as little as $0–$25/month. The card covers the difference between your copay and the maximum benefit amount. Available at wegovy.com. Not eligible: Medicare, Medicaid, TRICARE, VA, or other government-funded insurance.

Zepbound Savings Card: Similar program from Eli Lilly. Eligible commercially insured patients may pay $25/month or less. Available at zepbound.com. Same government insurance exclusions apply.

LillyDirect Self-Pay: For patients without insurance coverage, Eli Lilly offers Zepbound at approximately $550/month through their direct-to-consumer platform — roughly half the pharmacy list price.

Key strategy: Activate the savings card before filling your first prescription. Some pharmacies apply it automatically; others require you to present the card or provide the BIN/PCN numbers at the counter.

2. Patient Assistance Programs (PAPs)

For patients without insurance who meet income requirements, manufacturers offer free or deeply discounted medication:

Novo Nordisk PAP: Provides Wegovy at no cost to qualifying patients. Income requirements typically cap at 400% of the Federal Poverty Level. Application through novocare.com.

Lilly Cares: Eli Lilly’s patient assistance program for Zepbound/Mounjaro. Similar income-based eligibility. Application through lillycares.com.

These programs require documentation (tax returns, pay stubs) and annual re-enrollment. Processing takes 2–4 weeks. They’re designed for genuinely uninsured or underinsured patients, not as a way to avoid copays on an existing plan.

3. HSA/FSA Strategy

Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) can be used to pay for GLP-1 medications with pre-tax dollars, effectively reducing cost by 25–35% depending on your tax bracket.

The requirement: a Letter of Medical Necessity (LMN) from your physician documenting that the GLP-1 medication is medically necessary for treatment of obesity or a related condition. With an LMN, both brand-name and compounded GLP-1 medications qualify as HSA/FSA-eligible expenses.

For a patient spending $300/month on compounded semaglutide, using HSA funds saves approximately $75–$105/month in taxes — bringing the effective cost down to $195–$225/month.

4. The Wegovy Pill: Built-In Savings

At $149/month for the starting dose and $299/month for maintenance, the Wegovy pill is already priced as a “savings program” compared to the $1,349/month injectable. No coupon or savings card needed — the price is the price. This makes it the simplest affordable option for uninsured patients who want an FDA-approved product.

5. State-Level Programs

Some states have their own pharmaceutical assistance programs that may cover GLP-1 medications for residents who meet income criteria. Check with your state’s Department of Health or pharmaceutical assistance program for eligibility.

Additionally, states with GLP-1 coverage mandates (North Dakota, Connecticut, Delaware, Maryland, New Jersey, Vermont, West Virginia) require fully-insured plans to cover these medications. If you’re in one of these states and your insurer denies coverage, you may have grounds for a complaint with your state insurance commissioner.

6. Compounded GLP-1s as a Savings Strategy

For patients without insurance and without eligibility for assistance programs, compounded semaglutide at $150–$400/month remains an option. While not FDA-approved, it provides the same active molecule at a fraction of the brand-name injectable price. The Wegovy pill has narrowed this advantage, but compounding programs may still be cheaper at certain doses, particularly during the titration phase.

When comparing compounded vs. self-pay brand options, calculate the Total Monthly Cost (medication + consultation fees + shipping) for an apples-to-apples comparison.